atezolizumab
FDA Approves Tecentriq as Adjuvant Rx for Stage II-IIIA NSCLC
The FDA approved atezolizumab (Tecentriq, Genentech) for adjuvant treatment after resection and platinum-based ...
OCTOBER 29, 2021
Atezolizumab Combo Regimen Approved for ES-SCLC
Tecentriq (Genentech) is the first new treatment option for this type of lung cancer in more than 20 years, ...
MARCH 19, 2019
Tecentriq Combo Approved for First-Line Rx of Metastatic Nonsquamous NSCLC
The FDA approved atezolizumab (Tecentriq, Genentech) in combination with bevacizumab (Avastin, Genentech), ...
DECEMBER 19, 2018
FDA Modifies Indications of Pembrolizumab, Atezolizumab
The FDA modified the urethal cancer indications of Keytruda and Tecentriq, limiting their use to patients who are ...
JULY 3, 2018
FDA Warns of Decreased Survival in Some UC Patients on Keytruda or Tecentriq
The FDA issued an alert about decreased survival associated with the use of pembrolizumab (Keytruda, Merck) or ...
MAY 21, 2018
